89bio Inc (ETNB)
7.90
+0.12
(+1.54%)
USD |
NASDAQ |
May 31, 16:00
7.90
0.00 (0.00%)
After-Hours: 20:00
89bio SG&A Expense (Annual): 28.97M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 28.97M |
December 31, 2022 | 21.45M |
December 31, 2021 | 19.41M |
Date | Value |
---|---|
December 31, 2020 | 13.16M |
December 31, 2019 | 5.294M |
December 31, 2018 | 1.481M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
5.294M
Minimum
2019
28.97M
Maximum
2023
17.66M
Average
19.41M
Median
2021
SG&A Expense (Annual) Benchmarks
Akero Therapeutics Inc | 31.07M |
Madrigal Pharmaceuticals Inc | 108.15M |
Viking Therapeutics Inc | 37.02M |
Galectin Therapeutics Inc | 5.942M |
Terns Pharmaceuticals Inc | 39.06M |